Feature | July 30, 2014

Incisionless TAVR Surgery Associated with Shorter Hospital Stays

July 30, 2014 — New research from Penn Medicine shows that incisionless transcatheter aortic valve replacement (TAVR) surgery cuts lengths of hospital stay by 30 percent and has no impact on post-operative vascular complication rates when compared with conventional transfemoral TAVR, which requires an incision in the groin. The complete study is available in the current issue of Circulation: Cardiovascular Interventions.

TAVR surgery can be performed in two ways, both involving the insertion of a sheath into the femoral artery, which allows the new valve to be threaded up to the patient’s chest via a catheter. The traditional transfemoral approach requires a several-inch incision in the groin. More recently, physicians have begun to employ an incisionless or percutaneous approach, which requires no more than a pinprick to access the femoral artery. Patients leave the hospital without an incision of any kind and little to no trace that a surgery was performed.

“It has been our clinical experience that there is little difference in vascular outcomes between traditional and percutaneous TAVR surgery, but we wanted to take a closer look at the data and understand how these techniques performed in a side-by-side comparison on vascular complications, outcomes and hospital length of stay,” said senior author Jay Giri, M.D., MPH, assistant professor in the division of cardiovascular medicine at the Perelman School of Medicine at the University of Pennsylvania.

Giri and his co-authors examined 120 patients who underwent TAVR via the traditional method and 211 patients who had percutaneous TAVR surgery at the Hospital of the University of Pennsylvania or Penn Presbyterian Medical Center between 2007 and 2013. They observed a shorter post-procedural length of hospital stay (7.5 versus 9.9 days) in patients who received percutaneous surgery versus traditional TAVR surgery and no difference in vascular complication rates between the two procedures.

Vascular complications can include hematomas, large bruises under the skin; dissections, tears in the vessel walls putting the vessels at risk for closure; and the rupture of blood vessels, among others. The Penn researchers discovered that vascular complications were tied to the sex of the patient, with females appearing to be at greater risk of complications than males. This issue will be the subject of further research.

Higher rates of vascular complications were also associated with larger valve introducer sheath outer diameter compared to patients’ artery diameter. The introducer sheaths can easily nick or disrupt the vessels in transit and cause complications for the patient, whether they have traditional or percutaneous surgery. “While there are clinical circumstances when oversized sheaths must be used to accomplish a life-saving procedure, we discovered that, contrary to conventional wisdom, there really is no such thing as a ‘safe oversize,’” says Giri.

Previous studies had not examined the association of percutaneous and traditional surgery approaches with vascular complications in a wide cross section of patients with the full range of sheath sizes available in the United States. This is also the first study to show increasing harm with increasing sheath oversizing. Vascular complication rates are expected to decrease as technology advances, and sheath sizes continue to decrease in relation to artery diameter. Currently, however, the authors warn, careful preprocedural planning with respect to the relationship between sheath size and artery diameter is warranted.

For more information: www.uphs.upenn.edu

Related Content

Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
Edwards Lifesciences, completes acquisition, Valtech Cardio
News | Heart Valve Technology| January 25, 2017
Edwards Lifesciences Corp. announced that it has closed its acquisition of Valtech Cardio Ltd., developer of the...
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart| January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
TAVR, medical guidelines, ACC/AHA, optimization, transcatheter aortic valve replacement
News | Heart Valve Technology| January 18, 2017
The American College of Cardiology recently released new guidance for clinicians and hospitals to use in assessing...
Medtronic, CoreValve Evolut R 34 mm valve, TAVI, CE Mark, European launch
News | Heart Valve Technology| January 17, 2017
Medtronic plc announced the CE (Conformité Européenne) mark and European launch of the CoreValve Evolut R 34 mm valve...
Tendyne Mitral valve

The Tendyne mitral valve being implanted. 

News | Heart Valve Technology| January 16, 2017
January 16, 2017 – In 2015, researchers and physicians at the Minneapolis Heart Institute Foundation (MHIF) were the
BioTrace Medical, first U.S. patients, Tempo Temporary Pacing Lead, EP lab, TAVR
News | Leads Implantable Devices| January 13, 2017
BioTrace Medical Inc. announced in December the first commercial use of the company’s Tempo Temporary Pacing Lead since...
RECHORD Trial, Neochord DS1000 System, mitral regurgitation, PinnacleHealth, first Pennsylvania patient
News | Heart Valve Technology| January 06, 2017
The RECHORD trial allows cardiovascular surgeons to replace damaged string-like tendons, called chordae, through a...
Hitachi, Vector Flow Mapping, TedMed 2016, Partho Sengupta, holographic evaluation of cardiac valves
News | Cardiovascular Ultrasound| January 04, 2017
January 4, 2017 — A new ground-breaking technology that allows evaluation of...
Overlay Init